Lumora’s commercialisation strategy has evolved since the company’s inception. The initial approach was to achieve commercial validation through licensing and collaboration with third parties. This has been highly successfully and was executed via the relationships with 3M and Biogal. Lumora is now on a pathway to begin commercializing clinical diagnostic and sample preparation products, under its own brand, during 2015.
In addition to the clinical products Lumora will be launching, a number of product lines for life science applications are now available.
These research reagents include products and technologies for sample prep, amplification and detection, as well as our instrument platforms the PDQ and Bison.
Lumora's BART technology has been exclusively licensed to 3M™ for the in vitro molecular testing in food, beverages and feed for animals, and is being successfully commercialized worldwide as the 3M™ Molecular Detection System.
Lumora is collaborating with Biogal Galed Labs to produce a range of veterinary products for companion animal diagnosis.
Lumora is presently working with leading companies, organisations and institutes on numerous projects to make molecular diagnostics easier to use and more widely available in a variety of clinical and non-clinical settings.
Lumora has numerous academic collaboration and relationships